Melanotan I: The Analogue That Only Exists as an Implant

Melanotan I is the melanocortin peptide with an approved medicine behind it. Under the name afamelanotide it prevents phototoxicity in erythropoietic protoporphyria. That disorder lets protoporphyrin accumulate in skin, where visible light then produces burning pain [9].

The approved product is not a peptide in solution. It is a 16 mg bioresorbable implant placed under the skin and replaced every 60 days [8]. Every controlled trial, every long-term cohort and every pigmentation measurement in this article came from that implant.

That distinction runs through the literature in a way most summaries skip. The sequence and the delivery system are separate subjects. The second one is where the clinical record lives.

Chemical identity

A linear tridecapeptide, capped at both ends, built on the alpha-melanocyte-stimulating hormone sequence with two deliberate substitutions.

The catalogue lists it as Melanotan I, 10 mg of lyophilised powder.

Reading the sequence

Both termini carry caps. An acetyl group sits on serine 1, and the C-terminal valine ends as an amide rather than a free acid. Capping both ends removes the substrates that aminopeptidases and carboxypeptidases recognise. That is the standard reason a peptide survives longer in serum.

Nine of the thirteen residues match the native hormone exactly. The interesting chemistry sits at positions 4 and 7.

The two substitutions that define it

The native hormone carries methionine at position 4, a residue whose thioether oxidises. Norleucine replaces it with a straight butyl side chain that carries no sulfur. The substitution keeps roughly the same shape and bulk while removing the oxidation liability.

Both molecules carry phenylalanine at position 7. In the analogue it takes the D configuration. That single inversion changes the local backbone geometry, and the resulting peptide resists the serum enzymes that clear the native hormone [1].

Everything the compound does differently follows from those two changes. The His-Phe-Arg-Trp pharmacophore shared by every melanocortin survives intact [15].

Melanotan I was reverse-engineered from a degradation product

The design did not start on a drawing board. Sawyer and colleagues at Arizona were working with heat and alkali treated alpha-MSH. That preparation darkened frog skin for far longer than the fresh hormone, and nobody knew why [1].

Quantitative gas chromatography of the hydrolysed material gave the answer. The harsh treatment had partly racemised the peptide, and the racemisation clustered at positions 4 and 7. Prolonged activity turned out to be a side effect of chemical damage.

So the group synthesised the damage on purpose. They made [Nle4]-alpha-MSH, which also gained prolonged activity after heat and alkali. Then they made [Nle4, D-Phe7]-alpha-MSH directly. The result resisted serum enzymes and ran 26 times as potent as the native hormone in the mouse melanoma adenylate cyclase assay [1].

What “ultralong” meant on frog skin

The 1980 title claims ultralong biological activity, and the claim is accurate against its comparator. Native alpha-MSH clears in minutes. Anything holding a frog skin dark for hours qualifies by that standard.

Read as a statement about dosing intervals in a mammal, it means much less. A 2023 study injected an equivalent dose of the peptide into frogs and lost the tanning response within a few days. An acylated self-assembling version of the same molecule held the response beyond four weeks [16]. The word describes a comparison, not a duration.

The receptor and what binding it does

MC1R is a class A G protein coupled receptor on melanocytes. Agonist binding raises cyclic AMP. That drives transcription of the pigment enzymes and shifts melanin synthesis toward eumelanin, the darker of the two polymers.

A solved structure

A 2021 paper reported three cryo-electron microscopy structures of the human MC1R-Gs complex [15]. One holds the native hormone, one holds Melanotan I, and one holds the synthetic agonist SHU9119. Few compounds in this catalogue have a receptor complex solved with the compound itself in the pocket.

Two findings stand out. The conserved His-Phe-Arg-Trp motif occupies the orthosteric site in all three, which explains why melanocortin analogues resist selectivity engineering. A calcium ion also sits in the binding pocket and ligand recognition depends on it, a feature most peptide receptors lack [15].

Potency at the human receptor

A Swiss group built a cell assay to test whether patients develop neutralising antibodies during prolonged exposure. The assay read cyclic AMP formation in a B16 mouse melanoma line transfected with the human receptor. It produced clean half-effective concentrations along the way: 38.8 plus or minus 10.6 nM for the native hormone, against 10.9 plus or minus 7.17 nM for the analogue [4].

Roughly a fourfold gap, well below the 26-fold figure from 1980. Different assay, different receptor species, different readout. Neither number contradicts the other, and neither describes potency in a person.

The antibody question itself came back negative. Sera from 17 drug-exposed patients neutralised no more than sera from six drug-naive ones. Prolonged exposure elicited nothing [4].

Pigment without light

The pathway runs from receptor to enzyme with no photon involved, and the disease indication depends on that property. Patients with erythropoietic protoporphyria cannot tolerate the light that would normally drive tanning. A pigment response requiring ultraviolet exposure is useless to them.

The opposite manipulation of the same pathway has its own catalogue entry. Glutathione sits on the depigmenting side of melanin chemistry. The two compounds pair usefully for anyone studying the pigment switch from both directions.

The pharmacodynamics of a single implant

One study measured what a single implant does, and it did so in a different disease. Five patients with solar urticaria received one 16 mg implant in winter. Reflectance spectrophotometry then tracked melanin density from day 0 to day 60 [2].

Density rose by day 7, peaked at day 15, and remained above baseline at day 60. All three timepoints separated from baseline statistically. The same study measured the functional consequence with monochromated light testing across 300 to 600 nm. Weal area fell across the responding wavelengths by day 60 [2].

The 60-day interval

That kinetic profile is the argument for dosing every 60 days, and it is thinner than it looks. The Rotterdam porphyria group states plainly in a 2021 review that the 60-day interval rests on no effectiveness study. They add that the resulting cap of four implants a year falls short for some patients [13].

An interval chosen without a dose-finding study is worth carrying into any protocol design. It is a regulatory artefact rather than a measured optimum.

The peptide without the implant

Melanotan I in solution and Melanotan I in a controlled-release matrix are not the same experiment. The frog work cited above puts an equivalent dose of free peptide at a few days of response. A formulation engineered to release slowly held it beyond four weeks [16].

Nothing in the clinical literature characterises the free peptide on its own. Every human number in this article came from a matrix that releases over weeks.

What the controlled trials measured

Two randomised, double-blind, placebo-controlled trials were run in parallel and published together in 2015 [8]. They remain the pivotal evidence.

Why the two numbers are not interchangeable

Same compound, same implant, same endpoint name, and medians differing by more than tenfold. The published report does not reconcile them. Read conservatively, the two trials counted qualifying sun exposure differently, and their absolute hours will not pool.

Ratios behave better than absolutes here. The American trial improved on placebo by a factor near 1.7 and the European one by a factor near 7.5, so even the ratios disagree. Phototoxic reaction counts came only from the European trial, at 77 against 146 on placebo [8].

What routine practice added

Two cohorts followed. An Italian and Swiss series covered 115 patients and 1,023 implants over eight years. Quality of life scores rose from 31 percent of maximum to 74 percent and stayed there [7]. A Dutch cohort of 117 patients ran as a post-authorisation study at the European regulator’s request, and it recorded 6.1 more hours a week spent outside alongside a 14.01 percent quality of life gain [11].

That Dutch study also produced the most useful negative result in this literature. Phototoxic reactions became less painful, while their number and duration did not change [11]. Whatever the treatment does, it does not reduce how often the reactions occur.

The indications that stayed pilots

Cells outside the melanocyte lineage also express MC1R, and receptor activation carries anti-inflammatory and antifibrotic effects alongside the pigment response [18]. Several small studies chased that, and none of them became a second approval.

Vitiligo

The largest randomised 55 patients with non-segmental vitiligo [6]. One arm received narrowband ultraviolet B alone, the other the same phototherapy plus monthly implants. Repigmentation at day 168 reached 48.64 percent against 33.26 percent, and the face and upper limbs responded earlier in the combination arm.

The subgroup result is the interesting part. Patients with Fitzpatrick phototypes IV to VI improved on the vitiligo scoring index. Phototype III patients showed no significant difference [6]. A drug acting by making melanocytes produce more pigment does more where there is more pigment machinery to recruit.

Solar urticaria and acne

The solar urticaria study is the melanin-density work already described, five patients, no control arm [2]. The acne study is smaller still. Three patients, open label, with inflammatory lesion counts falling by day 56 and one report of mild short-term fatigue [3].

Three patients with no comparator generates a hypothesis. The authors of that report say as much in their own conclusion.

The pigmented-lesion question

Melanocortin agonists stimulate melanocytes, so whether they change moles is the obvious safety question. Two bodies of evidence answer it in different directions, because they describe different populations.

The dermoscopy series

An Italian group followed 103 acquired melanocytic naevi in 15 treated patients [14]. Clinical and dermoscopic examination ran at baseline, at five months and at twelve months. Reticular and two-component naevi showed focal thickening of the pigment network at five months, and by twelve months that had returned to baseline.

Globule counts rose at the same interim timepoint and also normalised. No dermoscopic feature suggesting malignancy appeared in any lesion, and no new naevi developed [14]. That is a prospective, supervised answer for the treated population.

The case reports on the other side

A 2017 review of unregulated alpha-MSH analogue use collected four published cases of melanoma. Each arose in an existing mole during or shortly after melanotan use [10]. The authors are careful. They state that conclusive evidence linking the two is lacking, and they note the warnings issued by several national health bodies.

The two literatures do not contradict each other. One describes a characterised implant under dermatological surveillance. The other describes self-injected material of unknown composition. That difference is the subject of the next section.

What the oral successor implies

A non-peptidic MC1R agonist reached late-stage development, and its discovery paper gives the reason in the first paragraph. Clinicians deliver afamelanotide as a subcutaneous implant, and the programme wanted a more convenient oral drug [18]. The compound is dersimelagon.

Preclinical work used Melanotan I as the reference comparator throughout [12]. The small molecule showed nanomolar agonism at human MC1R and concentration-dependent melanin production in melanoma cells. Oral dosing darkened mouse coats from 0.3 mg/kg/day and pigmented monkey skin from 1 mg/kg/day, reversing fully after withdrawal.

That is the same arc several compounds in this catalogue follow. A prototype defines a class and proves the target worth pursuing. Molecules designed against the prototype’s inconvenience, rather than against the disease, then overtake it.

The succession also created a methodological argument worth reading. Running a new agent against placebo when an approved treatment exists drew a formal ethical objection [17]. A 2025 analysis of 29 registered protocols went further, concluding that the outcome measures differ too widely for any trial to be compared with another [19].

The supply problem

Buyers of peptides outside a regulated supply chain rarely assay what they receive, and one study put numbers on what that means. The authors bought vials of the related compound melanotan II from three online shops. They then ran liquid chromatography with tandem mass spectrometry on each [5].

Every shop claimed 10 mg per vial. Measured content ran from 4.32 mg to 8.84 mg. Vials from two of the three carried unidentified impurities at 4.1 to 5.9 percent [5].

Those measurements describe melanotan II rather than this compound, and treating them as read-across is an assumption rather than a finding. The method transfers even where the numbers do not. Measurement is the only route to knowing what a vial holds.

This matters more here than for most compounds, because the trials built their entire clinical record on a controlled-release implant. A reported milligram figure for loose powder describes neither the same dose nor the same exposure profile as anything published.

How to read a Melanotan I study

Five questions separate the papers that are about this molecule from the papers that are not.

Which melanotan?

The names are close enough to swap by accident. Melanotan I is the linear tridecapeptide described here. Melanotan II is a cyclic heptapeptide with a lactam bridge, and bremelanotide is its deamidated relative. Check the sequence in the methods, not the name in the title.

Implant or solution?

Almost every human study used a 16 mg controlled-release implant. Bench work usually uses free peptide in buffer. A result obtained under one exposure profile does not transfer to the other without an argument.

Melanin or pain?

Pigmentation studies measure melanin density by reflectance spectrophotometry, which is objective and reproducible. Clinical studies measure pain-free hours outdoors, which is neither. The 2015 trials and the Dutch cohort disagree about phototoxic reaction counts while agreeing about pain [8][11]. Endpoint choice is why.

Assayed or assumed?

Case reports of adverse events after unregulated use almost never pair a dose with a content assay [10]. The reported milligram figure is what the person believed they injected.

Verifying research material

The peptide is a defined chemical entity with published identifiers, so verification is arithmetic rather than judgement. Batch documentation sits on the certificates of analysis page.

Identity

Molecular formula C₇₈H₁₁₁N₂₁O₁₉ and monoisotopic identity resolve to InChIKey UAHFGYDRQSXQEB-LEBBXHLNSA-N. Mass spectrometry should return a molecular weight near 1646.9. The practical precursor is the doubly charged ion, the same approach validated for its cyclic sibling [5].

Purity and stereochemistry

The D-phenylalanine at position 7 is the whole point of the molecule, and mass spectrometry cannot see it. An epimer at that position carries the same formula, the same mass and the native hormone’s susceptibility to proteolysis. Chiral amino acid analysis after hydrolysis answers the question. It is the same technique that revealed the racemisation in 1980 [1].

Handling

The sequence carries tryptophan and tyrosine, both of which absorb ultraviolet and photodegrade. Suppliers ship the material lyophilised for that reason. Reconstituted solutions of an unformulated peptide have none of the stabilisation an implant matrix provides.

Common questions about Melanotan I

Is Melanotan I the same thing as afamelanotide? Yes. The same sequence carries both names, along with NDP-alpha-MSH and the development code CUV1647.

Why is the approved product an implant rather than an injection? Because the free peptide’s duration of action is short relative to the treatment interval. Formulation work on acylated analogues designed to self-assemble makes the same point from the other side [16].

Is it selective for MC1R? More selective than its cyclic sibling, which is why it became a pigmentation drug rather than an abandoned programme. The shared His-Phe-Arg-Trp pharmacophore makes selectivity a matter of degree across the whole family [15].

What does the receptor do besides pigment? MC1R signalling has anti-inflammatory components, which is why the acne and vitiligo studies were run at all [3][6]. The evidence there remains pilot-scale.

How many people have been treated? More than 1,000 implants across 115 patients in one eight-year series, and 117 patients in a regulator-mandated Dutch cohort [7][11].

Summary of the evidence

Strongest evidence: two randomised placebo-controlled trials in erythropoietic protoporphyria [8], supported by an eight-year observational series [7] and a regulator-directed cohort [11]. A solved receptor complex with the compound in the pocket [15]. A quantified pigmentation time course from a single implant [2].

Weakest evidence: everything outside the licensed indication. Vitiligo rests on one 55-patient trial [6], acne on three open-label patients [3], solar urticaria on five uncontrolled patients [2].

Read plainly, Melanotan I is well characterised as a controlled-release implant in one rare disease and poorly characterised as anything else. The pigmented-lesion data reassure in the supervised population [14] and are absent for the unsupervised one [10].

Read the peptide literature in the peptides category for the rest of the melanocortin family.

Status: supplied for laboratory research use only.

References

1. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77(10):5754-5758. PMID 6777774. DOI
2. Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes LE. Systemic photoprotection in solar urticaria with alpha-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-alpha-MSH. Br J Dermatol. 2011;164(2):407-414. PMID 20969564. DOI
3. Böhm M, Ehrchen J, Luger TA. Beneficial effects of the melanocortin analogue Nle4-D-Phe7-alpha-MSH in acne vulgaris. J Eur Acad Dermatol Venereol. 2014;28(1):108-111. PMID 22845050. DOI
4. Spichty R, Balimann M, Barman J, Minder EI. A bioassay for the detection of neutralizing antibodies against the alpha-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria. J Pharm Biomed Anal. 2013;75:192-198. PMID 23277150. DOI
5. Breindahl T, Evans-Brown M, Hindersson P, McVeigh J, Bellis M, Stensballe A, Kimergård A. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015;7(2):164-172. PMID 24771717. DOI
6. Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151(1):42-50. PMID 25230094. DOI
7. Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601-1612. PMID 25494545. DOI
8. Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48-59. PMID 26132941. DOI
9. Lane AM, McKay JT, Bonkovsky HL. Advances in the management of erythropoietic protoporphyria: role of afamelanotide. Appl Clin Genet. 2016;9:179-189. PMID 28003770. DOI
10. Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017;56(10):975-980. PMID 28266027. DOI
11. Wensink D, Wagenmakers MAEM, Barman-Aksözen J, Friesema ECH, Wilson JHP, van Rosmalen J, Langendonk JG. Association of afamelanotide with improved outcomes in patients with erythropoietic protoporphyria in clinical practice. JAMA Dermatol. 2020;156(5):570-575. PMID 32186677. DOI
12. Suzuki T, Kawano Y, Matsumoto A, Kondo M, Funayama K, Tanemura S, Miyashiro M, Nishi A, Yamada K, Tsuda M, Sato A, Morokuma K, Yamamoto Y. Melanogenic effect of dersimelagon (MT-7117), a novel oral melanocortin 1 receptor agonist. Skin Health Dis. 2021;2(1):e78. PMID 35665216. DOI
13. Wensink D, Wagenmakers MAEM, Langendonk JG. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert Rev Clin Pharmacol. 2021;14(2):151-160. PMID 33507118. DOI
14. Arisi M, Rossi M, Rovati C, Tomasi C, Mori L, Laini L, Calzavara-Pinton PG. Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide. Photochem Photobiol Sci. 2021;20(2):315-320. PMID 33721252. DOI
15. Ma S, Chen Y, Dai A, Yin W, Guo J, Yang D, Zhou F, Jiang Y, Wang MW, Xu HE. Structural mechanism of calcium-mediated hormone recognition and Gbeta interaction by the human melanocortin-1 receptor. Cell Res. 2021;31(10):1061-1071. PMID 34453129. DOI
16. Chang CL, Cai Z, Hsu SYT. A gel-forming alpha-MSH analog promotes lasting melanogenesis. Eur J Pharmacol. 2023;958:176008. PMID 37673364. DOI
17. Barman-Aksözen J, Andreoletti M, Blasimme A. Current trials in erythropoietic protoporphyria: are placebo controls ethical? Orphanet J Rare Dis. 2023;18(1):325. PMID 37845740. DOI
18. Sato A, Morokuma K, Adachi T, Andou J, Miyashiro M, Suzuki T, Kawano Y, Kondo M, Ogasawara A, Ide M, Yamamoto Y. Discovery of MT-7117 (dersimelagon phosphoric acid): a novel, potent, selective, and nonpeptidic orally available melanocortin 1 receptor agonist. J Med Chem. 2024;67(24):21729-21748. PMID 39641249. DOI
19. Dechant C, Wäscher S, Granata F, Gusset N, Pettersson M, Aksözen MH, Höglinger M, Falchetto R, Barman-Aksözen J. New pharmacotherapies for the erythropoietic protoporphyrias: an analysis of trial protocols from a patient perspective. Orphanet J Rare Dis. 2025;20(1):637. PMID 41466311. DOI

Melanotan I is sold for laboratory research use only. Not for human consumption, nor medical, veterinary, or household uses.

Literature retrieved from PubMed.